Edesa Biotech, Inc.

Edesa Biotech, Inc., a biopharmaceutical business, works towards obtaining, creating, and making available medications for inflammatory and immunologic illnesses that have yet to be appropriately addressed. Its leading product applicants are EB05, an antibody that is currently in its third phase of clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, an external medication in Phase 2B clinical study intended to treat chronic allergic contact dermatitis. The company additionally has an agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 as well as CXCL10. Edesa Biotech, Inc. was created in 2015 and is based in Markham, Canada.